Australia’s first GLP-1 weight-loss tablets arrived on pharmacy shelves on Friday, giving patients a needle-free alternative to weekly injections. The oral medications, led by Novo Nordisk’s Wegovy, offer broadly similar appetite-suppressing effects to existing jabs while introducing new daily routines and private prescription costs.
What makes the Wegovy tablet different from injections?
The Wegovy daily tablet contains semaglutide, the same active ingredient found in the weekly weight-loss injections, according to reporting by 7NEWS. The medication became Australia’s first Therapeutic Goods Administration-cleared daily weight-loss pill this month, arriving at chemists on Friday, sbs.com.au reported.
“For many people, the needle has been a real barrier, whether that’s fear of injecting, a preference for tablets, or practical issues like travel and refrigeration,” said Dr Terri-Lynne South, Immediate Past Chair of the Royal Australian College of General Practitioners (RACGP) Specific Interests Obesity Management, as reported by RACGP.
Clinical trials show that adults taking the highest tablet dose lost about 14 per cent of their body weight on average over one year, compared with a 15 per cent loss over 68 weeks for patients on the standard 2.4mg weekly injection, 7NEWS reported.
“And this is so exciting for patients,” she told 7NEWS.
“We just know that some of the patients are really hesitant when it comes to injecting themselves with the medication,” she told 7NEWS.
“There will be people who were really put off by the fact it was only available as an injection that might be more interested (now),” she said, as reported by 7NEWS.
“You have to take [the Wegovy pill] at least half an hour before eating, and so that means a routine that you have to get into,” she said, according to SBS News.
“The current advice is that the side effects are similar to the injectables,” she said, according to 7NEWS.
“It will just fit in with what I do on a day-to-day basis,” she told the Australian Associated Press, as reported by SBS News.
Potential Benefits and Patient Options
Vancouver endocrinologist Dr. Ehud Ur discussed the potential weight-loss effectiveness of Eli Lilly’s daily tablet Foundayo with Global News, comparing its expected benefits with established treatments containing semaglutide and tirzepatide. He said that it seems to be just as good as if not better than existing options.
Monash University obesity medicine expert Associate Professor Priya Sumithran said that the considerations for choosing between the treatments would mostly be up to personal preference. She explained that patients can decide whether they prefer a once-a-week injection or a once-a-day tablet.
Wider Impacts and Treatment Access
The push to market from both pill-based weight loss drugs is likely to result in patients having discussions with their general practitioners about the best options available for their health, according to Dr Terri-Lynne South.
The arrival of oral treatments follows a surge in the use of GLP-1 drugs for diabetes and weight management in recent years.
How much do the new pills cost?
Wegovy tablets vary by dose, costing between $260 and $395 a month on private prescription, sbs.com.au reported. The medication is not currently listed on Australia’s Pharmaceutical Benefits Scheme, though the federal government is negotiating with Novo Nordisk to subsidize the drug for a small cohort of patients, which would reduce the price to $25 per script or $7.70 for concession card holders.
“Until obesity medicines are subsidised, access will be determined by what people can afford rather than by clinical need,” Dr South told sbs.com.au.
Another weight-loss pill, Eli Lilly’s Foundayo containing orforglipron, has also received approval from the Therapeutic Goods Administration, according to sbs.com.au and SuaraGarut.ID.
Foundayo can be taken at any time of day, whereas Wegovy requires a specific routine of being taken at least half an hour before eating, sbs.com.au reported.